FDA's CBD Puzzle: 'Criminals' Continue Or Prohibition Ends And Research Grows
Executive Summary
Agency seeks comment, at May 31 public hearing and docket open through July 2, on health and safety risks, manufacturing and product quality and marketing/labeling/sales around allowing cannabis-derived ingredients non-drug products. It wants input from across sectors of stakeholders, including opponents as well as proponents of allowing cannabis-derived ingredients in any category of regulated products other than drugs.
You may also be interested in...
Naturopath, Regulatory Expert MacKay Returns To DC As CHPA’s Supplement Industry Strategy Chief
Consumer Healthcare Products Association names Duffy MacKay as its first senior VP for dietary supplements. Former CRN executive moves from CV Sciences back into trade group world.
House Agriculture Chairman Plants Seeds For FDA's CBD Policy With First Bill
Minnesota Democrat Collin Peterson’s bill, the first targeting FDA’s CBD question, could provide an entire answer or it could set table for discussion in Congress about legislation on establishing an FDA regulation on using CBD, and potentially other hemp-derived substances, in products other than drugs subject to its oversight.
US Wellness Market In 2019: Farm Bill Made Cultivating Cannabidiol Policy FDA's Main Course In Supplements
As HBW Insight looks back on notable US wellness market developments and events for the previous 12 months, we find that news in the CBD space from the FDA and the industry dominated the sector throughout 2019.